Skip to main content

Table 1 Patient characteristics

From: Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

Characteristics N = 151
 Age, years 57 (52–63)
Sex
 Male 137 (90.7%)
 Female 14 (9.3%)
ECOG performance status
 0 52 (34.4%)
 1 97 (64.2%)
 2 2 (1.3%)
Etiology
 Hepatitis B 134 (88.7%)
 Hepatitis C 4 (2.6%)
 Alcohol 7 (4.6%)
 Others 6 (4.0%)
Child-Pugh class
 A 140 (92.7%)
 B 11 (7.3%)
BCLC stage
 B 5 (3.3%)
 C 146 (96.7%)
Macrovascular invasion
 Yes 63 (41.7%)
 No 88 (58.3%)
No. of extrahepatic spread organ sites
 0 15 (9.9%)
 1 79 (52.3%)
 2 41 (27.2%)
  ≥ 3 16 (10.6%)
Sites of extrahepatic spread
 Lymph node 64 (42.4%)
 Lung 77 (51.0%)
 Bone 32 (21.2%)
 Peritoneum 23 (15.2%)
 Adrenal gland 13 (8.6%)
AFP (ng/mL)
  < 20 41 (27.1%)
 20–200 32 (21.2%)
  > 200 77 (51.0%)
 Not available 1 (0.7%)
 Platelet count (× 103/mm3) 122.0 (85.0–165.0)
 Prothrombin time (INR) 1.08 (1.02–1.16)
 Albumin (g/dL) 3.7 (3.4–4.0)
 Total bilirubin (mg/dL) 0.7 (0.5–1.0)
 AST (IU/L) 39 (28–58)
 ALT (IU/L) 26 (18–39)
Previous therapy
 No 10 (6.6%)
 Yes 141 (93.4%)
 Surgical resection 69 (45.7%)
 RFA 37 (24.5%)
 TACE 118 (78.1%)
 Radiotherapy 79 (52.3%)
 Liver transplantation 12 (7.9%)
  1. Data are the median (interquartile range) or number (%) unless otherwise indicated
  2. ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP alpha fetoprotein, INR international normalized ratio, AST aspartate aminotransferase, ALT alanine aminotransferase, RFA radiofrequency ablation, TACE transcatheter arterial chemoembolization